Avastin (bevacizumab) / Roche - LARVOL DELTA

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer (clinicaltrials.gov) - P1 | N=207 | Recruiting | Sponsor: AbbVie

Adverse events • First-in-human • Monotherapy • New P1 trial • Platinum resistant • Oncology • Ovarian Cancer • Solid Tumor

Feasibility of Extending Urine Protein Monitoring Frequency for Patients on Bevacizumab (ASHP 2025) - No abstract available

Clinical

Incidence of Infusion Related Reactions with Rapid Infusion Protocols for Bevacizumab Products (ASHP 2025) - No abstract available

Clinical

Incidence of White Blood Cell Toxicity and Infections in Patients Treated with Trifluridine/Tipiracil Plus Bevacizumab in Real-World Practice (ASHP 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Infectious Disease

Does oncogeriatric screening tool (OST) predict survival in older patients with metastatic colorectal cancer (mCRC)? (SIOG 2025) - "Most pts received monotherapy (63% capecitabine [CPC], 13% CPC-bevacizumab, 24% doublet). The OST effectively identifies patients with poorer prognosis and predicts improved outcomes with chemotherapy. It facilitates personalized treatment decisions, helping to avoid unnecessary toxicity. Appropriately adapted CT in pre-frail patients significantly improves OS."

Clinical • Metastases • Colorectal Cancer • Oncology • Solid Tumor

First-line modified-FOLFIRI plus bevacizumab or panitumumab in older patients with metastatic colorectal cancer: results of two parallel phase II trials from Hellenic Oncology Research Group (SIOG 2025) - " Patients ≥70 years old with unresectable mCRC were treated with bevacizumab (5mg/Kgr) in tumors with KRAS/RAS mutant or unknown status (study A) or Panitumumab 6mg/kg as 60min iv infusion in KRAS/NRAS wild type tumors (study B) followed by mFOLFIRI (irinotecan 130mg/m2 as 90min iv infusion, calcium folinate 400mg/m2 as 2 hours iv infusion and 5-fluorouracil 400mg/m2 as bolus iv infusion on day 1 and 5-fluorouracil 1.200 mg/m2 as continuous iv infusion for 46 hours), every 2 weeks. The mFOLFIRI plus bevacizumab or panitumumab combination presented significant efficacy with manageable toxicity as 1st-line treatment in patients ≥70 years old with mCRC."

Clinical • Metastases • P2 data • Colorectal Cancer • Oncology • Solid Tumor • KRAS

Real-world treatment patterns and outcomes in elderly patients with metastatic colorectal – a Portuguese single-center experience (SIOG 2025) - "In this cohort, systemic therapy was common, but treatment intensity and median OS decreased with age; doublet vs monotherapy did not significantly impact OS, and older pts were less likely to receive later-line therapies."

Clinical • HEOR • Metastases • Real-world • Real-world evidence • Colorectal Cancer • Oncology • Solid Tumor

First-line modified-FOLFIRI plus bevacizumab or panitumumab in older patients with metastatic colorectal cancer: results of two parallel phase II trials from Hellenic Oncology Research Group (SIOG 2025) - " Patients ≥70 years old with unresectable mCRC were treated with bevacizumab (5mg/Kgr) in tumors with KRAS/RAS mutant or unknown status (study A) or Panitumumab 6mg/kg as 60min iv infusion in KRAS/NRAS wild type tumors (study B) followed by mFOLFIRI (irinotecan 130mg/m2 as 90min iv infusion, calcium folinate 400mg/m2 as 2 hours iv infusion and 5-fluorouracil 400mg/m2 as bolus iv infusion on day 1 and 5-fluorouracil 1.200 mg/m2 as continuous iv infusion for 46 hours), every 2 weeks. The mFOLFIRI plus bevacizumab or panitumumab combination presented significant efficacy with manageable toxicity as 1st-line treatment in patients ≥70 years old with mCRC."

Clinical • Metastases • P2 data • Colorectal Cancer • Oncology • Solid Tumor • KRAS

Does oncogeriatric screening tool (OST) predict survival in older patients with metastatic colorectal cancer (mCRC)? (SIOG 2025) - "Most pts received monotherapy (63% capecitabine [CPC], 13% CPC-bevacizumab, 24% doublet). The OST effectively identifies patients with poorer prognosis and predicts improved outcomes with chemotherapy. It facilitates personalized treatment decisions, helping to avoid unnecessary toxicity. Appropriately adapted CT in pre-frail patients significantly improves OS."

Clinical • Metastases • Colorectal Cancer • Oncology • Solid Tumor

Real-world treatment patterns and outcomes in elderly patients with metastatic colorectal – a Portuguese single-center experience (SIOG 2025) - "In this cohort, systemic therapy was common, but treatment intensity and median OS decreased with age; doublet vs monotherapy did not significantly impact OS, and older pts were less likely to receive later-line therapies."

Clinical • HEOR • Metastases • Real-world • Real-world evidence • Colorectal Cancer • Oncology • Solid Tumor

Does oncogeriatric screening tool (OST) predict survival in older patients with metastatic colorectal cancer (mCRC)? (SIOG 2025) - "Most pts received monotherapy (63% capecitabine [CPC], 13% CPC-bevacizumab, 24% doublet). The OST effectively identifies patients with poorer prognosis and predicts improved outcomes with chemotherapy. It facilitates personalized treatment decisions, helping to avoid unnecessary toxicity. Appropriately adapted CT in pre-frail patients significantly improves OS."

Clinical • Metastases • Colorectal Cancer • Oncology • Solid Tumor

Does oncogeriatric screening tool (OST) predict survival in older patients with metastatic colorectal cancer (mCRC)? (SIOG 2025) - "Most pts received monotherapy (63% capecitabine [CPC], 13% CPC-bevacizumab, 24% doublet). The OST effectively identifies patients with poorer prognosis and predicts improved outcomes with chemotherapy. It facilitates personalized treatment decisions, helping to avoid unnecessary toxicity. Appropriately adapted CT in pre-frail patients significantly improves OS."

Clinical • Metastases • Colorectal Cancer • Oncology • Solid Tumor

Real-world treatment patterns and outcomes in elderly patients with metastatic colorectal – a Portuguese single-center experience (SIOG 2025) - "In this cohort, systemic therapy was common, but treatment intensity and median OS decreased with age; doublet vs monotherapy did not significantly impact OS, and older pts were less likely to receive later-line therapies."

Clinical • HEOR • Metastases • Real-world • Real-world evidence • Colorectal Cancer • Oncology • Solid Tumor

First-line modified-FOLFIRI plus bevacizumab or panitumumab in older patients with metastatic colorectal cancer: results of two parallel phase II trials from Hellenic Oncology Research Group (SIOG 2025) - " Patients ≥70 years old with unresectable mCRC were treated with bevacizumab (5mg/Kgr) in tumors with KRAS/RAS mutant or unknown status (study A) or Panitumumab 6mg/kg as 60min iv infusion in KRAS/NRAS wild type tumors (study B) followed by mFOLFIRI (irinotecan 130mg/m2 as 90min iv infusion, calcium folinate 400mg/m2 as 2 hours iv infusion and 5-fluorouracil 400mg/m2 as bolus iv infusion on day 1 and 5-fluorouracil 1.200 mg/m2 as continuous iv infusion for 46 hours), every 2 weeks. The mFOLFIRI plus bevacizumab or panitumumab combination presented significant efficacy with manageable toxicity as 1st-line treatment in patients ≥70 years old with mCRC."

Clinical • Metastases • P2 data • Colorectal Cancer • Oncology • Solid Tumor • KRAS

First-line modified-FOLFIRI plus bevacizumab or panitumumab in older patients with metastatic colorectal cancer: results of two parallel phase II trials from Hellenic Oncology Research Group (SIOG 2025) - " Patients ≥70 years old with unresectable mCRC were treated with bevacizumab (5mg/Kgr) in tumors with KRAS/RAS mutant or unknown status (study A) or Panitumumab 6mg/kg as 60min iv infusion in KRAS/NRAS wild type tumors (study B) followed by mFOLFIRI (irinotecan 130mg/m2 as 90min iv infusion, calcium folinate 400mg/m2 as 2 hours iv infusion and 5-fluorouracil 400mg/m2 as bolus iv infusion on day 1 and 5-fluorouracil 1.200 mg/m2 as continuous iv infusion for 46 hours), every 2 weeks. The mFOLFIRI plus bevacizumab or panitumumab combination presented significant efficacy with manageable toxicity as 1st-line treatment in patients ≥70 years old with mCRC."

Clinical • Metastases • P2 data • Colorectal Cancer • Oncology • Solid Tumor • KRAS

Real-world treatment patterns and outcomes in elderly patients with metastatic colorectal – a Portuguese single-center experience (SIOG 2025) - "In this cohort, systemic therapy was common, but treatment intensity and median OS decreased with age; doublet vs monotherapy did not significantly impact OS, and older pts were less likely to receive later-line therapies."

Clinical • HEOR • Metastases • Real-world • Real-world evidence • Colorectal Cancer • Oncology • Solid Tumor

Reframing Breast Cancer Therapies in a Rare Context - A Case of Metastatic Mammary-Like Vulvar Carcinoma Treated with Breast Cancer Regimens (SABCS 2025) - "She received adjuvant radiation with concurrent cisplatin. Given HER2 positivity, she was treated with six cycles of docetaxel, trastuzumab, and pertuzumab, followed by maintenance trastuzumab and pertuzumab...She was treated with olaparib from February to November 2023. Following disease progression, she transitioned to trastuzumab deruxtecan for HER2-low disease, which resulted in temporary disease control between December 2022 to May 2024. Upon further progression, she received carboplatin, paclitaxel, and bevacizumab, completing six cycles in May 2024, followed by maintenance bevacizumab and pembrolizumab... MLVA is an extremely rare malignancy with no established standards of care. Its histologic resemblance to breast cancer suggests it may respond to breast cancer-based therapies. In the absence of defined treatment pathways, applying breast cancer therapeutic strategies—particularly in the metastatic setting—may offer a rational and effective approach for managing..."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • BRCA2 • ER • GATA3 • HER-2 • PAX8 • PGR • SOX10

Sacituzumab Govitecan Combined with Anti-angiogenic Therapy and Radiotherapy in a BRCA1-Mutated Triple-Negative Breast Cancer Patient with Multiple Recurrences: A Case Report (SABCS 2025) - P2 | "She underwent left modified radical mastectomy, followed by 8 cycles of adjuvant chemotherapy (epirubicin + cyclophosphamide, followed by paclitaxel)...In December 2020, right chest wall recurrence was found, treated with local extended resection in January 2021, and followed by one-year oral capecitabine.In June 2023, she developed lung metastases (germline BRCA1 mutation),then enrolled in an IIT trial (NCT05085626) where she received Fluzoparib + Chidamide, achieving partial response (PR) with a progression-free survival (PFS) of 14 months...She declined brain surgery and received Bevacizumab + Trastuzumab Deruxtecan...Treatment with SG in combination with Anlotinib was initiated, accompanied by concurrent WBRT during the first cycle... This case report highlights the potential efficacy of SG in combination with anti-angiogenic therapy and radiotherapy in treating BRCA1-mutated TNBC patients with multiple recurrences and brain metastases. However, further studies..."

Case report • Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BRCA • BRCA1 • HER-2 • HRD • PGR

Basal-like residual disease after neoadjuvant chemotherapy is immunologically cold and associated with poor prognosis in triple negative breast cancer CALGB 40603 (Alliance) (SABCS 2025) - "In this study, we performed transcriptomic profiling on 340 pre-treatment and 70 matched post-treatment RD samples from the CALGB 40603 Phase II trial, which evaluated the effects of adding carboplatin or bevacizumab to a neoadjuvant chemotherapy (NACT) regimen of weekly paclitaxel, followed by dose-dense doxorubicin and cyclophosphamide, in patients with stage II/III TNBC...We therefore tested the antibody-drug conjugates (ADCs) sacituzumab govitecan and trastuzumab deruxtecan on a basal-like patient-derived xenograft model established from a pre-treatment biopsy of a "basal-basal" TNBC patient who ultimately had RD following conventional NACT...We show that in early-stage TNBC, prognostic features measured in RD specimens following NACT may be different from those in the pre-treatment setting, providing a rationale for prognostic biomarker development in the RD setting. Substantial immune depletion in basal-like RD may have implications for treatments with..."

Clinical • IO biomarker • Residual disease • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CCND1 • CDK6 • HER-2 • TACSTD2

Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - P1/2 | N=792 | Recruiting | Sponsor: Hoffmann-La Roche | N=580 ➔ 792 | Trial completion date: May 2028 ➔ Sep 2030 | Trial primary completion date: May 2028 ➔ Sep 2030

Enrollment change • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PD-L1 • PIK3CA

Cytokine score based on expression levels of multiple cytokines is a prognostic indicator in metastatic breast cancer patients treated with chemotherapy (SABCS 2025) - " Of the patients, 46.5% (n = 20) were treated with eribulin, 9.3% (n = 4) with trastuzumab deruxtecan, 9.3% (n = 4) with paclitaxel and bevacizumab, 7.0% (n = 3) with trastuzumab emtansine, and 27.9% (n = 12) with other chemotherapeutic agents. Our results show that the levels of TNF-α, sIL-2R, IL-6, and TK1 were associated with outcomes in patients with MBC treated with chemotherapy. The cytokine score, based on the number of elevated cytokines, is an important prognostic indicator for both OS and PFS. Furthermore, since a high cytokine score was associated with higher levels of MDSCs, and lower levels of CD4+ and CD8+ lymphocytes, the cytokine score might be associated with patient outcomes through immune reaction."

Biomarker • Clinical • Metastases • Breast Cancer • Oncology • Solid Tumor • CD4 • CD8 • CXCL8 • IL2 • IL6 • TGFB1 • TNFA

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases (clinicaltrials.gov) - P2 | N=140 | Recruiting | Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Not yet recruiting ➔ Recruiting | Initiation date: Apr 2025 ➔ Oct 2025

Enrollment open • Mismatch repair • pMMR • Trial initiation date • Colorectal Cancer • Oncology • Solid Tumor • BRAF

FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. (PubMed) - "Bevacizumab 10 mg/kg plus FOLFIRI as second-line treatment did not prolong PFS compared with bevacizumab 5 mg/kg plus FOLFIRI in patients with mCRC. If bevacizumab is continued after first-line therapy in mCRC, a dose of 5 mg/kg is appropriate for use as second-line treatment."

Journal • Biosimilar • Colorectal Cancer • Oncology

Phase I Study of Bevacizumab and Temsirolimus Combination Therapy in Advanced Malignancies: Safety, Efficacy, and Ovarian Cancer Expansion. (PubMed, Oncologist) - P1 | "Combination therapy showed acceptable safety and modest activity. Molecular and imaging findings were exploratory and limited. These preliminary observations could inform future biomarker studies. (ClinicalTrials.gov Identifier: NCT01552434)."

Journal • P1 data • Cardiovascular • Fatigue • Gastrointestinal Disorder • Oncology • Ovarian Cancer • Pulmonary Embolism • Respiratory Diseases • Solid Tumor

Overall Survival for Bevacizumab Therapy in Metastatic Colorectal Cancer: An Updated Analysis of the TRAVASTIN Study. (PubMed, Clin Colorectal Cancer) - "Plasma Tie2 is a response biomarker for PFS benefit with first-line bevacizumab in metastatic colorectal cancer, although OS benefit was not significant in TRAVASTIN. Our study highlights the promising use of Tie2 to guide bevacizumab treatment, including retreatment, in colorectal cancer."

Journal • Colorectal Cancer • Oncology • Solid Tumor